Investigation of the prognostic value of TNF-α gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-α production and apoptosis

Pathobiology

Volumn 71, Issue 5, 2004, Pages 274-280

  Balog, Attila ^a   Klausz, Gergely ^a   Gál, János ^b   Molnár, Tamás ^a   Nagy, Ferenc ^a   Ocsovszky, Imre ^a   Gyulai, Zsófia ^a   Mándi, Yvette ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b 1st Department of Internal Medicine   (Hungary)

Author keywords

Apoptosis; Crohn's disease; Gene polymorphism; Infliximab; Intracellular cytokine; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; CYTOKINE; FLUORESCEIN ISOTHIOCYANATE; INFLIXIMAB; LIPOCORTIN 5; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALLELE; APOPTOSIS; ARTICLE; BIOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DNA POLYMORPHISM; EX VIVO STUDY; FLOW CYTOMETRY; GENOTYPE; HEREDITY; HUMAN; IN VITRO STUDY; MEASUREMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RHEUMATOID ARTHRITIS;

ALLELES; ANTIBODIES, MONOCLONAL; APOPTOSIS; ARTHRITIS, RHEUMATOID; BLOOD DONORS; CROHN DISEASE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENOTYPE; HUMANS; LEUKOCYTES, MONONUCLEAR; POLYMORPHISM, GENETIC; PROGNOSIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 5644233733     PISSN: 10152008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000080062     Document Type: Article

References (27)

1. Feldmann M, Brennan MF, Maini RN: Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
2. Hampe J, Shaw SH, Saiz R, Leysens N, Lantermann A, Mascheretti S, Lynch NJ, MacPherson AJS, Bridger S, van Deventer S, Stokkers P, Morin P, Mirza MM, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME, Schreiber S: Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999;65:1647-1655.
3. D'Haens G, van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P: Endoscopic and histological healing with infliximab antitumor necrosis factor antibodies in Crohn's disease: A European multicenter trial. Gastroenterology 1999;116:1029-1134.
4. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-1602.
5. Keystone EC: Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 2001;27:427-443.
6. Wilson AG, de Vreis N, Poicot F, di Giovine FS, van der Putte LBA, Duff GW: An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993;177:557-560.
7. Bouma G, Crusius JBA, Oudrek PM, Kolkman JJ, von Blomberg BME, Kostense PJ, Giphart MJ, Schreuder GM, Meuwissen SG, Pena AS: Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles. Relevance for inflammatory bowel disease. Scand J Immunol 1996;43:456-463.
8. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor α promoter on transcriptional activation. Proc Natl Acad Sci USA 1997;94:3195-3199.
9. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, Mahieu P, Malaise M, De Groote D, Louis R, Belaiche J: Tumour necrosis factor (TNF) gene polymorphism influences TNF-α production in lipopolysaccharide (LPS)-stimulated whole blood cell cultures in healthy humans. Clin Exp Immunol 1998;113:401-406.
10. Louis E, Peeters M, Franchimont D, Seidel L, Fontaine F, Demolin G, Croes F, Dupont P, Davin L, Omri S, Rutgeerts P, Belaiche J: Tumour necrosis factor (TNF) gene polymorphism in Crohn's disease (CD): Influence on disease behaviour? Clin Exp Immunol 2000;119:64-68.
11. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC: Anti-tumour necrosis factor agents and tuberculosis risk: Mechanism of action and clinical management. Lancet Infect Dis 2003;3:148-155.
12. Andus T, Stange EF, Hoffler D, Keller-Stanislawski B: Suspected cases of severe side effects after infliximab (Remicade) in Germany (in German). Med Klin (Munich) 2003;98:429-436.
13. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ: The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients. Gastroenterology 2004;126:19-31.
14. van Deventer SJH: Review article: Targeting TNFα as a key cytokine in the inflammatory processes of Crohn's disease - the mechanisms of action of infliximab. Aliment Pharmacol Ther 1999;13(suppl 4):3-8, discussion 38.
15. Papadakis KA, Targan SR: Tumor necrosis factor: Biology and therapeutic inhibitors. Gastroenterology 2000;119:1148-1157.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-324.
17. Podolsky DK: Inflammatory bowel disease. N Engl J Med 1991;325:928-937.
18. Wilson AG, Giovine FS, Blakemore AIF, Duff GW: Single base polymorphism in the human tumour necrosis factor alpha gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992;1:353.
19. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. Scand J Immunol 1986;24:739-743.
20. Megyeri K, Mándi Y, Degré M, Rosztóczy I: Induction of cytokine production by different Staphylococcal strains. Cytokine 2002;19:206-212.
21. Vatay A, Bene L, Kovacs A, Prohaszka Z, Szalai C, Romics L, Fekete B, Karadi I, Füst G: Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics 2003;55:247-252.
22. O'Dell JR: TNF-α inhibition: The need for a tumor necrosis factor thermostat. Mayo Clin Proc 2001;76:573-575.
23. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-1852.
24. Louis E, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, D'Haens G, Malaise M, Belaiche J: A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002;37:818-824.
25. Taylor KD, Plevy SE, Yang H, Landers CJ, Barry MJ, Rotter JI, Targan SR: ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology 2001;120:1347-1355.
26. Kaplan G, Freedman VH: The role of cytokines in the immune response to tuberculosis. Res Immunol 1996;147:565-572.
27. Lügering A, Schmidt M, Lügering N, Pauels HG, Domschike W, Kucharzik T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-1157.